BIIB Overview
Upcoming Projects (BIIB)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (BIIB)
-
Q4 #1: Discussing the current treatment landscape for Alzheimer's including Eisai/Biogen's Leqembi and Eli Lilly's recently approved Kisunla (donanemab).
Tickers: BIIB, ESAIY
Executed On: Oct 08, 2024 at 10:00 AM EDT -
A Third Look: Discussing the potential of a blood biomarker test to detect Alzheimer's disease and how it may impact the treatment landscape.
Tickers: BIIB, LLY, C2N Diagnostics
Executed On: Sep 14, 2024 at 09:30 AM EDT -
Investigating the topline data from the Phase 2/3 DEVOTE study of higher dose Spinraza (nusinersen) in patients with SMA
Ticker: BIIB
Executed On: Sep 11, 2024 at 01:00 PM EDT -
Q3 #3: Discussing the current treatment landscape for Alzheimer's including Eisai/Biogen's Leqembi and Eli Lilly's recently approved Kisunla (donanemab).
Tickers: BIIB, ESAIY
Executed On: Sep 10, 2024 at 12:00 PM EDT -
A Third View: Digging into the phase 2b trial of liraglutide in patients with Alzheimer's disease
Tickers: NVO, BIIB, LLY
Executed On: Aug 30, 2024 at 11:00 AM EDT -
A Second Look: Discussing the potential of a blood biomarker test to detect Alzheimer's disease and how it may impact the treatment landscape.
Tickers: C2N DIAGNOSTICS, LLY, BIIB
Executed On: Aug 29, 2024 at 09:00 AM EDT -
A Second View: Digging into the phase 2b trial of liraglutide in patients with Alzheimer's disease
Tickers: NVO, BIIB, LLY
Executed On: Aug 20, 2024 at 04:00 PM EDT -
Digging into the phase 2b trial of liraglutide in patients with Alzheimer's disease
Tickers: NVO, BIIB, LLY
Executed On: Aug 20, 2024 at 11:00 AM EDT -
Q3 #2: Discussing the current treatment landscape for Alzheimer's including Eisai/Biogen's Leqembi and Eli Lilly's recently approved Kisunla (donanemab).
Tickers: BIIB, ESAIY
Executed On: Aug 14, 2024 at 04:00 PM EDT -
Discussing the potential of a blood biomarker test to detect Alzheimer's disease and how it may impact the treatment landscape.
Tickers: C2N DIAGNOSTICS, LLY, BIIB
Executed On: Aug 05, 2024 at 04:00 PM EDT -
Q3 #1: Discussing the current treatment landscape for Alzheimer's including Eisai/Biogen's Leqembi and Eli Lilly's recently approved Kisunla (donanemab).
Tickers: BIIB, ESAIY
Executed On: Jul 31, 2024 at 06:00 PM EDT -
A Second Opinion: Speaking on the potential of Alzheon Inc's investigational oral agent ALZ-801/valiltramiprosate for Alzheimer's Disease
Tickers: ALZHEON INC., ESAIY, BIIB, LLY
Executed On: Jul 25, 2024 at 06:00 PM EDT -
Speaking on the potential of Alzheon Inc's investigational oral agent ALZ-801/valiltramiprosate for Alzheimer's Disease
Tickers: ALZHEON INC., ESAIY, BIIB, LLY
Executed On: Jul 16, 2024 at 01:30 PM EDT -
Q2 #5: Digging into the Alzheimer's Landscape: Comparing Eisai/Biogen's Leqembi & Lilly's donanemab and novel therapies in development.
Tickers: BIIB, ESAIY
Executed On: Jun 27, 2024 at 06:15 PM EDT -
Q2 #4: Digging into the Alzheimer's Landscape: Comparing Eisai/Biogen's Leqembi & Lilly's donanemab and novel therapies in development.
Tickers: BIIB, ESAIY
Executed On: Jun 06, 2024 at 04:00 PM EDT -
Q2 #3: Digging into the Alzheimer's Landscape: Comparing Eisai/Biogen's Leqembi & Lilly's donanemab and novel therapies in development.
Tickers: BIIB, ESAIY
Executed On: May 09, 2024 at 04:30 PM EDT -
Q2 #2: Digging into the Alzheimer's Landscape: Comparing Eisai/Biogen's Leqembi & Lilly's donanemab and novel therapies in development.
Tickers: BIIB, ESAIY
Executed On: May 01, 2024 at 03:00 PM EDT -
Q2 #1: Digging into the Alzheimer's Landscape: Comparing Eisai/Biogen's Leqembi & Lilly's donanemab and novel therapies in development.
Tickers: BIIB, ESAIY
Executed On: Apr 10, 2024 at 01:00 PM EDT -
5: Digging into the Alzheimer's Landscape: Comparing Eisai/Biogen's Leqembi & Lilly's donanemab and novel therapies in development
Tickers: BIIB, ESAIY
Executed On: Feb 23, 2024 at 10:00 AM EST -
4: Digging into the Alzheimer's Landscape: Eisai/Biogen's Leqembi and novel therapies in development.
Tickers: BIIB, ESAIY
Executed On: Feb 20, 2024 at 02:00 PM EST -
3: Digging into the Alzheimer's Landscape: Comparing Eisai/Biogen's Leqembi & Lilly's donanemab and novel therapies in development
Tickers: BIIB, ESAIY, LLY
Executed On: Feb 15, 2024 at 05:00 PM EST -
A second look at how payers within the U.S. are strategizing the reimbursement of Alzheimer's drugs such as Aducanumab (Aduhelm) and Lecanemab (Leqembi).
Ticker: BIIB
Executed On: Feb 14, 2024 at 01:00 PM EST -
A Third Look: Discussing the abstract data on the Phase 2a Study Of TMS-007, an SMTP family anti-inflammatory prothrombolytic, on patients with Acute Ischemic Stroke (AIS) up to 12 hours after onset
Tickers: JI-XING, BIIB
Executed On: Feb 05, 2024 at 06:00 PM EST -
A Second Look: Discussing the abstract data on the Phase 2a Study Of TMS-007, an SMTP family anti-inflammatory prothrombolytic, on patients with Acute Ischemic Stroke (AIS) up to 12 hours after onset
Tickers: JI-XING, BIIB
Executed On: Jan 30, 2024 at 05:00 PM EST -
A Second View: Digging into the Alzheimer's Landscape: Comparing Eisai/Biogen's Leqembi & Lilly's donanemab and novel therapies in development
Tickers: LLY, ESAIY, BIIB
Executed On: Jan 26, 2024 at 01:00 PM EST -
Discussing the abstract data on the Phase 2a Study Of TMS-007, an SMTP family anti-inflammatory prothrombolytic, on patients with Acute Ischemic Stroke (AIS) up to 12 hours after onset
Tickers: JI-XING, BIIB
Executed On: Jan 24, 2024 at 09:00 AM EST -
Digging into the Alzheimer's Landscape: Comparing Eisai/Biogen's Leqembi & Lilly's donanemab and novel therapies in development
Tickers: ESAIY, BIIB, LLY
Executed On: Jan 05, 2024 at 03:00 PM EST -
Checking in with a prescriber of Biogens Qalsody for the slowing of ALS progression.
Tickers: BIIB, AMLX
Executed On: Dec 19, 2023 at 10:00 AM EST -
A Second Look: Discussing the potential of Biogen's BIIB080 and the results from the Phase 1b study of BIIB080 presented at the CTAD conference.
Ticker: BIIB
Executed On: Nov 09, 2023 at 12:30 PM EST -
A look at the data presented at the CTAD conference for Eisai's and Biogen's LEQEMBI and Lilly's Donanemab in Alzheimer’s Disease.
Tickers: LLY, BIIB
Executed On: Nov 08, 2023 at 03:30 PM EST -
Discussing the potential of Biogen's BIIB080 and the results from the Phase 1b study of BIIB080 presented at the CTAD conference.
Ticker: BIIB
Executed On: Nov 07, 2023 at 03:00 PM EST -
A Third Look: Discussing the standard of care for Alzheimer's Disease and the potential of Alnylam Pharmaceuticals ALN-APP
Tickers: ALNY, BIIB, QTRX, DGX
Executed On: Sep 13, 2023 at 05:30 PM EDT -
A look at how payers within the U.S. are strategizing the reimbursement of Alzheimer's drugs such as Aducanumab (Aduhelm) and Lecanemab (Leqembi).
Ticker: BIIB
Executed On: Sep 13, 2023 at 10:00 AM EDT -
A Second Look: Discussing the standard of care for Alzheimer's Disease and the potential of Alnylam Pharmaceuticals ALN-APP
Tickers: ALNY, BIIB, QTRX, DGX
Executed On: Sep 08, 2023 at 05:00 PM EDT -
A Fourth View: Looking at the Alzheimer's Landscape with a focus on Lilly's Donanemab compared to Biogen's Leqembi.
Tickers: LLY, BIIB
Executed On: Aug 24, 2023 at 10:00 AM EDT -
A Third View: Looking at the Alzheimer's Landscape with a focus on Lilly's Donanemab compared to Biogen's Leqembi.
Tickers: LLY, BIIB
Executed On: Aug 11, 2023 at 09:00 AM EDT -
Discussing the standard of care for Alzheimer's Disease and the potential of Alnylam Pharmaceuticals ALN-APP
Tickers: ALNY, QTRX, BIIB, DGX
Executed On: Aug 09, 2023 at 12:00 PM EDT -
A Second View: Looking at the Alzheimer's Landscape with a focus on Lilly's Donanemab compared to Biogen's Leqembi.
Tickers: LLY, BIIB
Executed On: Jul 07, 2023 at 02:30 PM EDT -
A Second View: Discussing the Alzheimer's landscape with focus on Biogen's Lecanemab in light of the recent FDA approval
Tickers: EISAI, BIIB
Executed On: Jun 21, 2023 at 05:15 PM EDT -
Discussing the Alzheimer's landscape with focus on Biogen's Lecanemab in light of the recent FDA approval
Tickers: EISAI, BIIB
Executed On: Jun 20, 2023 at 05:00 PM EDT -
Looking at the Alzheimer's Landscape with a focus on Lilly's Donanemab compared to Biogen's Leqembi.
Tickers: LLY, BIIB
Executed On: May 23, 2023 at 01:00 PM EDT -
Gaining perspective on Biogen's Tofersen (BIIB067) recently approved for the treatment of ALS
Ticker: BIIB
Executed On: May 11, 2023 at 10:00 AM EDT -
Delving into the recent phase 3 VALOR clinical trial data on Biogen's Tofersen (BIIB067)
Ticker: BIIB
Executed On: Mar 08, 2023 at 12:00 PM EST -
Getting a better look at the current treatment landscape for Alzheimer's Disease and the current use of Biogen's Aduhelm.
Ticker: BIIB
Executed On: Feb 28, 2023 at 05:00 PM EST -
A second follow up on Biogen's Lecanemab after presentation of the Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer’s Disease at the Clinical Trials On Alzheimer’s Disease (Ctad) Conference
Tickers: BIIB, ESALY
Executed On: Dec 07, 2022 at 09:00 AM EST -
A follow up on Biogen's Lecanemab after presentation of the Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer’s Disease at the Clinical Trials On Alzheimer’s Disease (Ctad) Conference
Tickers: BIIB, ESALY
Executed On: Dec 05, 2022 at 12:00 PM EST -
A Third View: Discussing the Alzheimer's landscape with focus on Biogen's Lecanemab in light of the recent phase 3 topline data
Tickers: BIIB, Eisai
Executed On: Oct 06, 2022 at 12:30 PM EDT -
A Second View: Discussing the Alzheimer's landscape with focus on Biogen's Lecanemab in light of the recent phase 3 topline data
Tickers: BIIB, Eisai
Executed On: Oct 03, 2022 at 06:30 PM EDT -
Discussing the Alzheimer's landscape with focus on Biogen's Lecanemab in light of the recent phase 3 topline data
Tickers: BIIB, Eisai
Executed On: Oct 03, 2022 at 04:45 PM EDT -
A Second Look at the Skylark study and discussing Zuranolone in postpartum depression (PPD)
Tickers: SAGE, BIIB
Executed On: Jun 21, 2022 at 06:00 PM EDT -
A Third Look at the Skylark study and discussing Zuranolone in postpartum depression (PPD)
Tickers: SAGE, BIIB
Executed On: Jun 21, 2022 at 04:45 PM EDT -
A Look at the Skylark study and discussing Zuranolone in postpartum depression (PPD)
Tickers: SAGE, BIIB
Executed On: Jun 13, 2022 at 01:00 PM EDT -
A Second View: Discussing Aduhelm in Alzheimer's Disease
Ticker: BIIB
Executed On: Mar 10, 2022 at 04:15 PM EST -
Discussing Aduhelm in Alzheimer's Disease
Ticker: BIIB
Executed On: Mar 08, 2022 at 01:30 PM EST -
As data continues to released on Zuranolone in major depressive disorder, what does the CORAL study say about the drug's future?
Tickers: SAGE, BIIB
Executed On: Mar 04, 2022 at 03:00 PM EST
Upcoming & Overdue Catalysts (BIIB)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (BIIB)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
